Abu Dhabi Biobank partners with Human Life CORD Japan to advance stem cell therapies in UAE

Abu Dhabi Biobank has announced a strategic partnership with Human Life CORD Japan Inc (HLC) to develop and manufacture umbilical cord-derived stem cell therapies locally. The collaboration combines Abu Dhabi's biobanking infrastructure with Japan's stem cell technology expertise.

The partnership aims to create the UAE's first localized manufacturing pathway for Umbilical Cord Mesenchymal Stem Cell (UC-MSC) therapies. This could expand access to regenerative treatments across the UAE and wider Middle East region, supporting Abu Dhabi's push to become a global healthcare hub.

How will it work?

The collaboration brings together complementary capabilities from both organizations:

• Abu Dhabi Biobank provides large-scale biobanking infrastructure and public cord blood banking services
• Human Life CORD contributes proprietary MSC technology and clinical development expertise
• The partnership will establish GMP (Good Manufacturing Practice) manufacturing facilities for stem cell therapies
• Both organizations will develop clinical translation pathways from biospecimen collection to patient treatment

The initiative will focus on developing therapies for conditions common in the MENA region, including diabetes complications, musculoskeletal degeneration, and age-related conditions. Human Life CORD has already advanced multiple MSC-based treatments through clinical trials in Japan.

Why does it matter?

Umbilical cord-derived stem cell therapies offer significant advantages over conventional treatments for several chronic conditions. These therapies have shown immunomodulatory, anti-inflammatory, and tissue-repair properties that could restore function rather than just manage symptoms.

The partnership addresses several key healthcare challenges:

• Reduces reliance on imported stem cell treatments by establishing local manufacturing
• Creates therapies tailored to regional disease patterns and genetic profiles
• Builds regional resilience in advanced healthcare capabilities
• Supports Abu Dhabi's shift from reactive to preventive healthcare

"This partnership is a powerful example of how advanced biobanking infrastructure can be directly connected to therapeutic innovation," said Paul Downey, General Manager of Abu Dhabi Biobank.

The context

This collaboration is part of broader efforts to position Abu Dhabi as a global life sciences hub. Abu Dhabi Biobank is a joint initiative between the Department of Health - Abu Dhabi and M42, a global health technology company.

The partnership also strengthens scientific collaboration between the UAE and Japan in advanced medical research. Japan has been a leader in regenerative medicine research and clinical applications, while the UAE has been rapidly building its healthcare infrastructure and research capabilities.

Stem cell therapy represents a growing market globally, with increasing clinical applications for conditions where traditional treatments have limited effectiveness. By establishing local manufacturing capabilities, Abu Dhabi aims to reduce treatment costs and improve access for patients across the region while building expertise in this emerging field.